Author
Listed:
- Victoria Rollason
(Geneva University Hospitals and University of Geneva)
- Médéric Mouterde
(University of Geneva)
- Youssef Daali
(Geneva University Hospitals and University of Geneva)
- Martina Čížková
(Charles University)
- Edita Priehodová
(Charles University)
- Iva Kulichová
(Charles University)
- Helena Posová
(Charles University)
- Jitka Petanová
(Charles University)
- Anwar Mulugeta
(Addis Ababa University)
- Eyasu Makonnen
(Addis Ababa University
Addis Ababa University)
- Abir Al-Habsi
(Oman Specialty Board)
- Robin Davidson
(Sultan Qaboos University Hospital)
- Khalid K. Al-Balushi
(Sultan Qaboos University)
- Khalid Al-Thihli
(Sultan Qaboos University Hospital)
- Marie Cerná
(Charles University)
- Said Al-Yahyaee
(College of Medicine and Health Sciences)
- Viktor Černý
(Charles University)
- Getnet Yimer
(The Ohio State University)
- Estella S. Poloni
(University of Geneva
Institute of Genetics and Genomics of Geneva (iGE3))
- Jules Desmeules
(Geneva University Hospitals and University of Geneva)
Abstract
Introduction and Objective Cytochrome P450 enzymes are the major drug-metabolizing enzymes in humans and the importance of drug transport proteins, in particular P-glycoprotein, in the variability of drug response has also been highlighted. Activity of cytochrome P450 enzymes and P-glycoprotein can vary widely between individuals and genotyping and/or phenotyping can help assess their activity. Several phenotyping cocktails have been developed. The Geneva cocktail is composed of a specific probe for six different cytochrome P450 enzymes and one for P-glycoprotein and was used in the context of a research aiming at exploring genotypes and phenotypes in distinct human populations (NCT02789527). The aim of the present study is to solely report the safety results of the Geneva cocktail in the healthy volunteers of these populations. Materials and Methods The Geneva cocktail is composed of caffeine, bupropion, flurbiprofen, omeprazole, dextromethorphan, midazolam, and fexofenadine. The volunteers fasted and avoided drinking caffeine-containing beverages or food and grapefruit juice overnight before receiving the cocktail orally. They provided blood spots for the probes’ concentrations at 2, 3, and 6 h after ingestion and were asked about adverse events. Results A total of 265 healthy adult volunteers were included from Ethiopia, Oman, and the Czech Republic. The mean plasma concentrations at the 2-h sampling time of each probe drug in the total sample were: 1663 ng/mL for caffeine, 8 ng/mL for bupropion, 789 ng/mL for flurbiprofen, 6 ng/mL for dextromethorphan, 2 ng/mL for midazolam, 35 ng/mL for fexofenadine, and 103 ng/mL for omeprazole. Four adverse events were observed representing an occurrence of 1.5%. All these events were categorized as mild to moderate, non-serious, and resolved spontaneously. A causal link with the cocktail cannot be excluded because of the temporal relationship but is at most evaluated as possible according to the World Health Organization-Uppsala Monitoring Centre causal assessment system. Conclusions In this research, healthy volunteers from three different human populations were phenotyped with the Geneva cocktail. Four adverse events were observed, confirming the safety of this cocktail that is given at lower than clinically relevant doses and therefore results in concentrations lower than those reported to cause adverse events.
Suggested Citation
Victoria Rollason & Médéric Mouterde & Youssef Daali & Martina Čížková & Edita Priehodová & Iva Kulichová & Helena Posová & Jitka Petanová & Anwar Mulugeta & Eyasu Makonnen & Abir Al-Habsi & Robin Dav, 2020.
"Safety of the Geneva Cocktail, a Cytochrome P450 and P-Glycoprotein Phenotyping Cocktail, in Healthy Volunteers from Three Different Geographic Origins,"
Drug Safety, Springer, vol. 43(11), pages 1181-1189, November.
Handle:
RePEc:spr:drugsa:v:43:y:2020:i:11:d:10.1007_s40264-020-00983-8
DOI: 10.1007/s40264-020-00983-8
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:43:y:2020:i:11:d:10.1007_s40264-020-00983-8. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.